Pomix will receive from Ramot a worldwide license to use molecules to treat fungal infections

Pomix will have exclusive rights to develop and commercialize organo-boron compounds that will mainly help in the fight against fungal infection that affects the nails of the toes and hands

Foamix Ltd., which specializes in the development of pharmaceutical foams for the field of dermatology and gynecology, and Ramot, the commercialization company of Tel Aviv University, announced that the commercial terms of a worldwide and exclusive license for the use of antifungal molecules to treat fungal infections have been agreed upon.

According to the terms of the agreement, Poemix will have exclusive rights to develop and commercialize organo-boron compounds developed at Tel Aviv University by Prof. Amichai Freeman and his research team. These compounds were tested and found to have real potential for treating fungal infections.

The global market for antifungal preparations is estimated at more than 11 billion dollars in 2007 and will reach up to about 14 billion dollars by 2012. An increase of 4.5% per year. Total sales of antifungal drugs for vaginal skin use reach 3 billion dollars. The organo-boron compounds developed at Tel Aviv University will help mainly in the fight against fungal infection that affects the nails of the toes and hands - a disease that occupies a market share of 1.7 billion dollars (in 2005).

"This agreement is further evidence that Pomix continues its commitment to developing innovative treatments for skin diseases and important gynecological problems," says Dr. Dov Tamarkin, CEO of Pomix. "We believe that treatment with organo-boron compounds represents a promising treatment approach for fungal diseases. These compounds are a significant addition to Pomix's future development plan in the field of dermatology and gynecology."

"We are proud to be business partners with a leading development company like Poemix" says Ms. Irit Ben-Sheleh, the business development manager (in the field of life sciences) at "Ramot". She further added that "Pomex has earned the status of a leading drug development company through a number of significantly successful projects with world-class pharmaceutical partners, and we are convinced that the collaboration with Pomex will provide the best opportunity for the organo-boron drugs developed at Tel Aviv University to reach the market successfully" .

Foamix Foamix is ​​an Israeli pharmaceutical development company operating in the Weizmann Science Park in Rehovot. Foamix specializes in the development of topical dermatological (medicines for skin diseases) and gynecological products using foam technology: prescription drugs, over-the-counter (OTC) products and cosmetic preparations. Poemix is ​​a private company whose essential part of its business model is based on carrying out development projects in cooperation with leading pharmaceutical companies. As of today, Poemix has ten active projects in the diverse field of dermatological and gynecological medical preparations with eight pharmaceutical companies. Also, another variety of products developed as part of a unique independent R&D.

Poemix has diverse research and development capabilities that include development from the planning stages and the construction of the formulation to the gimelon stages, production under GMP conditions, clinical and pre-clinical trial processes, etc. The company has four registered patents in the USA and 62 patent applications in the USA. In addition, the company has many international filings.

For more information you can visit the company's website www.foamix.co.il